ACR Meeting Abstracts

ACR Meeting Abstracts

Session » Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy IV: Safety of Targeted Therapies

Date: Monday, November 9, 2015

Time: 4:30PM-6:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

Abstract Number: 2138
Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
Abstract Number: 2139
Results of a Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 2140
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Abstract Number: 2141
Risk of Cancer in Non-TNFi Biologics-Treated RA
Abstract Number: 2142
Comparison of Interferon-y Release Assay Versus Tuberculin Skin Test in the Golimumab UC and the Golimumab SC Rheumatology (RA, PsA, and AS) Clinical Study Programs
Abstract Number: 2143
A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population

« View all sessions from this meeting